
Kluwer Patent Blog

Patent case: Biogen MA Inc. vs. Sandoz B.V., Neuraxpharm Pharmaceuticals S.L. and Mylan B.V., Netherlands

Bart van Wezenbeek (Hoffmann Eitle) · Friday, March 21st, 2025

Biogen has had mixed success in Europe in enforcing its patent on a second medical use of dimethylfumarate for the treatment of multiple sclerosis. In the present Dutch case, an attempt to obtain an injunction against three different generic companies resulted in a counterclaim for revocation of the (Dutch part of the) European patent. Biogen was not able to convince the court of the patent's validity.

Case date: 22 January 2025

Case number: C/09/639604, HA ZA 22-1028, C/09/639606 , HA ZA 22-1029, C/09/639609, HA ZA 22-1030

Court: District Court of The Hague

A full summary of this case has been published on [Kluwer IP Law](#)

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please [subscribe here](#).

2024 Future Ready Lawyer Survey Report

Legal innovation: Seizing the future or falling behind?

[Download your free copy →](#)

 Wolters Kluwer



This entry was posted on Friday, March 21st, 2025 at 4:03 pm and is filed under [Case Law](#), [Injunction](#), [Netherlands](#), [Pharma](#), [Unitary Patent](#)

You can follow any responses to this entry through the [Comments \(RSS\) feed](#). You can leave a response, or [trackback](#) from your own site.